SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing
29 Febrero 2024 - 7:35AM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, today announced that it has successfully completed
the manufacturing of and delivered its innovative SCI- 210
treatment, in accordance with its initiation of enrollment for the
clinical trial at the Soroka Medical Center of pediatric patients
who have Autism Spectrum Disorder ("ASD").
The Company's proprietary SCI- 210 treatment
combines cannabidiol-rich oil (“CBD”) and CannAmide™, SciSparc’s
proprietary palmitoylethanolamide-based tablets.
"A clinical trial is a complicated project
composed of many little steps- which in turn help ensure successful
execution. Having the clinical supply ready on site is the final
step before first patient is administered treatment. We are
extremely excited to achieve this milestone and are confident in
the potential of our treatment to improve patients’ lives by
providing them with a more effective and safe treatment. Our unique
technology allows us to use lower doses of the active agent, which
leads to increased safety without harming its effectiveness" said
SciSparc’s Chief Executive Officer, Oz Adler. "We hope that the
outcome of this clinical trial will enable the Company to procced
with its commercialization of SCI- 210 in Israel."
The clinical trial will rigorously examine the
safety, tolerability, and efficacy of SCI- 210, in comparison to
CBD monotherapy, for the treatment of ASD. Designed as a
randomized, double-blind, placebo-controlled clinical trial with
cross-over, the clinical trial will span 20 weeks and enroll 60
children. The clinical trial's primary efficacy endpoints include
three rigorous assessments: the Aberrant Behavior
Checklist-Community (ABC-C) parent questionnaire; the Clinical
Global Impressions-Improvement (CGI-I) scale, administered by
healthcare professionals; and the determination of the effective
therapeutic dosage.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive CBD: SCI-110 for the treatment of
Tourette Syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI- 210 for the
treatment of ASD and status epilepticus. The Company also owns a
controlling interest in a subsidiary whose business focuses on the
sale of hemp seeds oil-based products on the Amazon.com
Marketplace.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses the Company’s belief
in the potential of its treatment to improve patients’ lives, that
the outcome of the clinical trial will enable the Company to
proceed with commercialization of SCI- 210 in Israel, and the
design of the upcoming clinical trial. Historical results of
scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will
suggest identical or even similar conclusions. Because such
statements deal with future events and are based on SciSparc's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under
the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the SEC on May 1, 2023, and in subsequent filings
with the U.S. Securities and Exchange Commission. Except as
otherwise required by law, SciSparc disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investor Contact: IR@scisparc.com Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024